Early biological markers for early warning of cytokine release syndrome occurrence and severity in relapsed/refractory multiple myeloma treated with CAR-T
Objective:To investigate the role of early biological markers of chimeric antigen receptor T cell(CAR-T)therapy for relapsed/refractory multiple myeloma(R/R MM)in early warning of the occurrence and se-verity of cytokine release syndrome(CRS).Methods:Fifty-six patients with R/R MM who were treated with CAR-T cells and underwent early biomarker testing from October 2020 to January 2023 in the Department of He-matology,Affiliated Hospital of Xuzhou Medical University,were enrolled in this study.The relationship be-tween changes in the concentration levels of 14 biological markers and the occurrence and severity of CRS in the first 3 days after CAR-T cell infusion were analyzed.Results:CRS occurred in 47(83.9％)patients,including 43(76.8％)with mild CRS(grade 1-2)and 4(7.1％)with severe CRS(grade 3-5).The median time to the onset of CRS was day 8(4-23)after CAR-T cell infusion,and the median duration was 3 days(1-12).The levels of IL-6(OR=1.018,95％CI 1.000-1.036)and IL-10(OR=1.038,95％CI 1.002-1.074)concentrations in the early pe-riod after cell transfusion were strongly correlated with the occurrence and severity of CRS,and the sensitivity of the combined warning of the occurrence of CRS with IL-6 and IL-10 was 65.96％with a specificity of 100.00％,and the sensitivity of warning the occurrence of severe CRS(≥ grade 3)was 100.00％and the specificity was 55.77％.Conclusion:Early in CAR-T therapy,both IL-6 and IL-10 can warn of CRS,and the combination of the two has higher sensitivity.
multiple myelomachimeric antigen receptor T cellcytokine release syndromeinterleukin-6interleukin-10
万方数据
维普
